Table 1 Baseline characteristics of the patients (n = 61)
Variables | TIMI flow 3 (n = 30) | TIMI flow 1–2 (n = 31) | p value |
|---|---|---|---|
Age (years) | 54.63 ± 8.98 | 57.10 ± 14.13 | 0.419 |
Male, n (%) | 26 (86.7%) | 26 (83.9%) | 1.000 |
Hypertension, n (%) | 5 (16.7%) | 11 (35.5%) | 0.095 |
Diabetes mellitus, n (%) | 6 (20%) | 7 (22.6%) | 0.806 |
Smoking, n (%) | 17 (56.7%) | 12 (38.7%) | 0.160 |
Family history of CAD, n (%) | 3 (10%) | 3 (9.7%) | 1.000 |
BMI (kg/m2) | 25.4 ± 4.17 | 25.10 ± 3.04 | 0.753 |
BSA (m2) | 1.74 ± 0.13 | 1.74 ± 0.12 | 0.891 |
Symptom to thrombolysis time (hours) | 4.77 ± 1.60 | 4.67 ± 1.47 | 0.809 |
Thrombolysis to PCI time (hours) | 16.03 ± 1.37 | 15.71 ± 1.40 | 0.377 |
Hemoglobin (g/dL) | 13.19 ± 1.85 | 13.31 ± 2.06 | 0.822 |
Creatinine (mg/dL) | 1.1 ± 0.17 | 1.07 ± 0.18 | 0.485 |
Total cholesterol (mg/dL) | 152.1 ± 52.85 | 139 ± 30.16 | 0.262 |
Triglycerides (mg/dL) | 134.1 ± 47.18 | 119.2 ± 40.82 | 0.208 |
LDL-cholesterol (mg/dL) | 100.8 ± 54.47 | 86.6 ± 33.42 | 0.247 |
HDL-cholesterol (mg/dL) | 38.18 ± 9.05 | 38.84 ± 11.74 | 0.814 |
CK-MB (IU/l) | 40 (36.25–53) | 37 (31 − 97.75) | 0.852 |
Ejection fraction, (%) | 43.40 ± 4.28 | 40.25 ± 6.34 | 0.027 |
Thrombolysis, n (%) | 0.656 | ||
Streptokinase | 24 (80%) | 22 (71%) | |
Reteplase | 6 (20%) | 8 (25.8%) | |
Tenecteplase | 0 (0%) | 1 (3.2%) | |
GP IIb-IIIa inhibitor use, n (%) | 11 (36.7%) | 10 (32.3%) | 0.717 |
Medications at admission (%) | |||
Antiplatelets (%) | 2 (6.6%) | 3 (9.6%) | 1.000 |
Statins (%) | 3 (10%) | 4 (12.9%) | 1.000 |
Beta blockers (%) | 2 (6.6%) | 5 (16.1%) | 0.425 |
ACE I/ARBs (%) | 4 (13.3%) | 5 (16.1%) | 1.000 |
OHAs (%) | 3 (10%) | 5 (16.1%) | 0.707 |
Insulin (%) | 2 (6.6%) | 1 (3.2%) | 0.612 |